Subscribe To
MACK / Merrimack Still Has Significant Arbitrage Potential
In December 2022, MACK got positive clinical results for its Phase III clinical trial of Onivyde in first line pancreatic cancer. A $225m milestone from Ipsen will be triggered on approval, which corresponds to about $16.75 per basic share.
Read More
Posted: Jan 4 2023, 10:33
Author Name: Seeking Alpha
Views: 102276
MACK News
By Seeking Alpha
January 4, 2023
Merrimack Still Has Significant Arbitrage Potential
In December 2022, MACK got positive clinical results for its Phase III clinical trial of Onivyde in first line pancreatic cancer. A $225m milestone fr more_horizontal